马立克病毒二价活疫苗效价检测实验

由于CVI988/Rispense疫苗优良的免疫特性,已经被认为是目前防控马立克氏病（Marek＇sdisease,MD）效果最好的疫苗。然而,近年来随着马立克病毒（Marek＇sdisease virus,MDV）毒力的不断增强。CVI988/Rispense需要与MDV-Ⅱ或者HVT联合使用才能防止免疫失败的发生。本实验通过空斑计数和间接免疫荧光相结合的方法测定了马立克病毒CVI988/Rispense＋FC126二价活疫苗的效价。结果显示批次A中CVI988为4400PFU/dose,HVT为2600/dose;批次B中CVI988为4800PFU/dose,HVT为2400PFU/dose;批次C中CVI988为4600PFU/dose,HVT为2800PFU/dose。所得结果均显著高于国家标准CVI988不少于2000PFU/dose,HVT不少于1000PFU/dose,并且批次之间非常稳定,适合用作鸡群马立克氏病的防控。

The Test of the CVI988/Rispense+FC126 Bivalent Live Vaccine Potency

CVI988/Rispense has become recognized as the gold standard due to its superior protection properties. With further increase in virulence of field viruses,CVI988/Rispense was combined with serotype Ⅱ or HVT to prevent the vaccine failure. The CVI988/Rispense＋FC126 bivalent live vaccine potency was determined by plage count and indirect immunofluorescence. The result display A batch include 4400PFU CVI988 and 2600PFU HVT per dose. B batch include 4800PFU CVI988 and 2400PFU HVT per dose. C batch include 4600PFU CVI988 and 2800PFU HVT per dose. These results siginificantly higher than government standard with CVI988 no fewer than 2000PFU and HVT no fewer than 1000PFU per dose. The reaearch showed that the potency is very stable between batches,so the bivalent live vaccine is suitable for Marek＇s disease prevention and control.